HUTCHMED Highlights Phase III SANOVO Trial Data in China
Phase III SANOVO in China showed ORPATHYS plus TAGRISSO significantly improved progression-free survival.
Phase III SANOVO in China showed ORPATHYS plus TAGRISSO significantly improved progression-free survival.